Case of Acquired Resistance to Crizotinib Described
A case of acquired resistance to crizotinib has been described in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement, according to research presented at ASCO 2013.
ASCO 2013
New Chaperone-Targeting Ganetespib Prolongs Survival in Advanced Lung Cancer
Adding ganetespib to docetaxel in salvage therapy prolongs OS compared to docetaxel alone among patients diagnosed with advanced adenocarcinoma lung cancer, research presented at ASCO 2013 has found.
Weekly Adjuvant Paclitaxel Offers Lower Post-Surgical Toxicity in Early-Stage Breast Cancer
Low-dose weekly paclitaxel and standard every-other-week paclitaxel dosing offer equivalent postsurgical PFS rates among women with higher-risk early-stage breast cancer, according to research presented at ASCO 2013.
Vinegar-Based Screenings Reduce Cervical Cancer Mortality by 31% Over 15 Years
Simple vinegar-based visual inspection screenings by primary paramedical health workers reduced cervical cancer mortality by 31% over 15 years, research presented at ASCO 2013 has found.
No Equivalence for Paclitaxel vs Doxorubicin/Cyclophosphamide as Adjuvant Treatment for Breast Cancer
Single-agent paclitaxel did not show equivalence to doxorubicin and cyclophosphamide as adjuvant therapy for breast cancer in women with zero to three axillary nodes, found data presented at ASCO 2013.
Bevacizumab Does Not Improve Survival in Newly-Diagnosed Glioblastoma
Among patients with newly-diagnosed glioblastoma, adding bevacizumab to standard first-line chemoradiotherapy does not improve survival, found data presented at ASCO 2013.
RT Offers Less Lymphedema, Comparable Breast Cancer Recurrence vs ALN Dissection
Axillary radiotherapy offers 5-year survival rates comparable to surgical dissection of the axillary lymph nodes, and a lower risk of lymphedema, according to research presented at ASCO 2013.
Continuing Tamoxifen to 10 Years Produces Further Reductions in Breast Cancer Recurrence, Death
Continuing adjuvant tamoxifen beyond 5 years in ER+ disease reduces breast cancer recurrence, with benefit occurring primarily after year 7, found research presented at ASCO 2013.
Bevacizumab plus Chemotherapy Extends Survival in Recurrent or Persistent Stage IVB Cervical Carcinoma
Bevacizumab extended survival in women with relapsed/advanced cervical cancer, the first time a targeted agent has significantly improved OS in gynecologic cancer, according to data presented at ASCO 2013.
Sorafenib Improves Progression-free Survival in Radioactive Iodine-refractory Metastatic Differentiated Thyroid Cancer
Sorafenib represents a potential new treatment option for patients with locally advanced or metastatic RAI-refractory differentiated thyroid cancer, according to research presented at ASCO 2013.
- Loading...
Loading...
Loading... 
Loading...